4.7 Article

Gold Nanopyramid Arrays for Non-Invasive Surface-Enhanced Raman Spectroscopy-Based Gastric Cancer Detection via sEVs

Journal

ACS APPLIED NANO MATERIALS
Volume 5, Issue 9, Pages 12506-12517

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsanm.2c01986

Keywords

surface-enhanced Raman spectroscopy (SERS); small extracellular vesicle; machine learning; liquid biopsy; non-invasive cancer detection; gastric cancer

Funding

  1. National Center for Advancing Translational Sciences at the National Institutes of Health [4UH3TR002978-03, 1U18TR003778-01]

Ask authors/readers for more resources

This study reports the potential of using surface-enhanced Raman spectroscopy (SERS) to detect gastric cancer through the composition information of Raman-active bonds inside small extracellular vesicles (sEVs). A machine learning-based spectral feature analysis algorithm was developed to objectively distinguish cancer-derived sEVs from non-cancer sub-population sEVs.
Gastric cancer (GC) is one of the most common and lethal types of cancer affecting over one million people, leading to 768,793 deaths globally in 2020 alone. The key for improving the survival rate lies in reliable screening and early diagnosis. Existing techniques including barium-meal gastric photofluorography and upper endoscopy can be costly and time-consuming and are thus impractical for population screening. We look instead for small extracellular vesicles (sEVs, currently also referred as exosomes) sized ? 30-150 nm as a candidate. sEVs have attracted a significantly higher level of attention during the past decade or two because of their potentials in disease diagnoses and therapeutics. Here, we report that the composition information of the collective Raman-active bonds inside sEVs of human donors obtained by surface-enhanced Raman spectroscopy (SERS) holds the potential for non-invasive GC detection. SERS was triggered by the substrate of gold nanopyramid arrays we developed previously. A machine learning-based spectral feature analysis algorithm was developed for objectively distinguishing the cancer derived sEVs from those of the non-cancer sub-population. sEVs from the tissue, blood, and saliva of GC patients and non-GC participants were collected (n = 15 each) and analyzed. The algorithm prediction accuracies were reportedly 90, 85, and 72%. Leave-a-pair-of-samples out validation was further performed to test the clinical potential. The area under the curve of each receiver operating characteristic curve was 0.96, 0.91, and 0.65 in tissue, blood, and saliva, respectively. In addition, by comparing the SERS fingerprints of individual vesicles, we provided a possible way of tracing the biogenesis pathways of patient-specific sEVs from tissue to blood to saliva. The methodology involved in this study is expected to be amenable for non-invasive detection of diseases other than GC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available